Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Nevro NVRO is well-poised for growth in ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist. This Zacks Rank #2 ...

The Prospera SCS system for pain management relieved pain, improved sleep and reduced opioid use at 24 months, according to ...

Spinal cord injuries are life-altering, often leaving individuals with severe mobility impairments. While rehabilitation ...

Nevro Corp. engages in the development of ... It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic ...

C. In a move to provide advanced solutions for chronic pain sufferers, OrthoNebraska is now offering minimally invasive ...

The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...